ReNewVax are pleased to announce the appointment of Simon Thorn as Chief Financial Officer.
An accomplished senior executive with significant expertise in the venture capital sector working hands-on with SME’s to help them to scale, prior to joining ReNewVax, Simon was Managing Partner at KPMG Acceleris for five years. He was with the firm for 20 years in total as a co-founder of Acceleris, a boutique venture capital fundraising advisory firm, which initially partnered with and was ultimately sold to KPMG UK in 2024.
Commenting on the appointment, Neil Murray, CEO, said, “We are delighted to have secured Simon as CFO to support the next phase of ReNewVax’s growth. His track record in fundraising across biotech and other sectors in both private and public markets will be a significant asset to ReNewVax going forwards. I look forward to working closely with Simon to drive the Company’s growth.
Simon Thorn added, “ReNewVax has an exciting opportunity to disrupt established vaccine markets with their innovative products, and I look forward to being part of the Company’s growth and success going forwards.”